Personalized interferon therapy aims to tame kidney disease without weakening defenses

NCT ID NCT05941845

Terminated Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether a personalized course of peginterferon alfa-2a can control membranous nephropathy, an autoimmune kidney disease. The treatment targets the Th17 inflammatory pathway, which is linked to a higher risk of relapse. Participants receive injections based on their immune profile, with the goal of reducing harmful antibodies and protein leakage without increasing infection risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peginterferon alfa-2a (Pegasys)
What this could lead to: If successful, this approach could offer a targeted, infection-sparing alternative to standard immunosuppressive treatments for membranous nephropathy.
What could go wrong: This is a very small early-phase trial with only 4 participants, so results may not generalize. Interferon therapy can cause flu-like symptoms and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

CHU de NICE

Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.